David Martin PhD
Stock Analyst at Bloom Burton
(4.73)
# 691
Out of 4,574 analysts
223
Total ratings
51.9%
Success rate
17.7%
Average return
Main Sectors:
Stocks Rated by David Martin PhD
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HELP Cybin | Maintained: Buy | $47 | $7.62 | +516.80% | 8 | Jul 21, 2026 | |
| TSX: APTX Apotex Health Corp. | Initiated Coverage: Buy | $40.00 | $35.94 | +11.30% | 1 | Jul 6, 2026 | |
| TSX: MDP Medexus Pharmaceuticals Inc. | Maintained: Buy | $6.00 | $5.04 | +19.05% | 13 | Jun 29, 2026 | |
| ZYME Zymeworks | Maintained: Buy | $35 → $36 | $22.86 | +57.48% | 13 | Jun 29, 2026 | |
| TSXV: RX BioSyent Inc. | Maintained: Buy | $16.50 → $18.00 | $14.74 | +22.12% | 14 | Jun 4, 2026 | |
| TSX: HLS HLS Therapeutics Inc. | Maintained: Buy | $12.00 | $4.05 | +196.30% | 50 | May 19, 2026 | |
| TSX: MBX Microbix Biosystems Inc. | Maintained: Buy | $0.50 → $0.40 | $0.30 | +33.33% | 13 | May 15, 2026 | |
| AUPH Aurinia Pharmaceuticals | Maintained: Hold | $15 | $15.35 | -2.28% | 33 | May 11, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Maintained: Buy | $11.00 → $12.00 | $9.73 | +23.33% | 28 | May 8, 2026 | |
| TSX: CRRX CareRx Corporation | Maintained: Buy | $5.50 → $5.00 | $3.38 | +47.93% | 11 | May 8, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $19.74 | $8.22 | +140.15% | 5 | Apr 27, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $4.00 → $5.00 | $1.66 | +201.20% | 3 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $57 → $74 | $65.42 | +13.12% | 8 | Mar 9, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $8.46 → $4.00 | $0.35 | +1,042.86% | 11 | Dec 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $9 | $5.31 | +69.49% | 6 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $14 | $19.27 | -27.50% | 1 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintained: Buy | $20.20 → $19.00 | $17.46 | n/a | 3 | Jul 18, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $1.00 | $0.17 | n/a | 2 | Jul 6, 2025 |
Cybin
Jul 21, 2026
Maintained: Buy
Price Target: $47
Current: $7.62
Upside: +516.80%
Apotex Health Corp.
Jul 6, 2026
Initiated Coverage: Buy
Price Target: $40.00
Current: $35.94
Upside: +11.30%
Medexus Pharmaceuticals Inc.
Jun 29, 2026
Maintained: Buy
Price Target: $6.00
Current: $5.04
Upside: +19.05%
Zymeworks
Jun 29, 2026
Maintained: Buy
Price Target: $35 → $36
Current: $22.86
Upside: +57.48%
BioSyent Inc.
Jun 4, 2026
Maintained: Buy
Price Target: $16.50 → $18.00
Current: $14.74
Upside: +22.12%
HLS Therapeutics Inc.
May 19, 2026
Maintained: Buy
Price Target: $12.00
Current: $4.05
Upside: +196.30%
Microbix Biosystems Inc.
May 15, 2026
Maintained: Buy
Price Target: $0.50 → $0.40
Current: $0.30
Upside: +33.33%
Aurinia Pharmaceuticals
May 11, 2026
Maintained: Hold
Price Target: $15
Current: $15.35
Upside: -2.28%
Knight Therapeutics Inc.
May 8, 2026
Maintained: Buy
Price Target: $11.00 → $12.00
Current: $9.73
Upside: +23.33%
CareRx Corporation
May 8, 2026
Maintained: Buy
Price Target: $5.50 → $5.00
Current: $3.38
Upside: +47.93%
Apr 27, 2026
Maintained: Buy
Price Target: $19.74
Current: $8.22
Upside: +140.15%
Mar 19, 2026
Maintained: Buy
Price Target: $4.00 → $5.00
Current: $1.66
Upside: +201.20%
Mar 9, 2026
Maintained: Buy
Price Target: $57 → $74
Current: $65.42
Upside: +13.12%
Dec 11, 2025
Maintained: Buy
Price Target: $8.46 → $4.00
Current: $0.35
Upside: +1,042.86%
Nov 19, 2025
Maintained: Buy
Price Target: $9
Current: $5.31
Upside: +69.49%
Oct 21, 2025
Maintained: Buy
Price Target: $14
Current: $19.27
Upside: -27.50%
Jul 18, 2025
Maintained: Buy
Price Target: $20.20 → $19.00
Current: $17.46
Upside: n/a
Jul 6, 2025
Initiated Coverage: Buy
Price Target: $1.00
Current: $0.17
Upside: n/a